The Marburgvirus Infections (Marburg Hemorrhagic Fever) drugs in development market research report provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Marburgvirus Infections (Marburg Hemorrhagic Fever). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued products.
GlobalData tracks 42 drugs in development for Marburgvirus Infections (Marburg Hemorrhagic Fever) by 34 companies/universities/institutes. The top development phase for Marburgvirus Infections (Marburg Hemorrhagic Fever) is preclinical with 27 drugs in that stage. The Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline has 32 drugs in development by companies and ten by universities/ institutes. Some of the companies in the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline products market are: Soligenix, Mapp Biopharmaceutical and Dominari.
The key targets in the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline products market include Tubulin beta chain, RNA, and Sodium/Potassium Transporting ATPase Subunit Alpha 3.
The key mechanisms of action in the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline product include Procathepsin L Inhibitor with one drug in Preclinical. The Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline products include seven routes of administration with the top ROA being Intramuscular and eight key molecule types in the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline products market including Subunit Vaccine, and Small Molecule.
Marburgvirus Infections (Marburg Hemorrhagic Fever) overview
Marburg hemorrhagic fever is a rare, acute infectious disease that affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain, and weight loss.
For a complete picture of Marburgvirus Infections (Marburg Hemorrhagic Fever)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
